China National Accord Medicines Inkomsten in het verleden
Verleden criteriumcontroles 2/6
China National Accord Medicines has been growing earnings at an average annual rate of 4.9%, while the Healthcare industry saw earnings growing at 2% annually. Revenues have been growing at an average rate of 8.2% per year. China National Accord Medicines's return on equity is 7.4%, and it has net margins of 2%.
Belangrijke informatie
4.9%
Groei van de winst
4.9%
Groei van de winst per aandeel
| Healthcare Groei van de industrie | 7.0% |
| Inkomstengroei | 8.2% |
| Rendement op eigen vermogen | 7.4% |
| Nettomarge | 2.0% |
| Laatste winstupdate | 30 Sep 2024 |
Recente prestatie-updates uit het verleden
Recent updates
China National Accord Medicines Corporation Ltd. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Oct 30
China National Accord Medicines (SZSE:000028) Seems To Use Debt Quite Sensibly
Oct 10China National Accord Medicines Corporation Ltd.'s (SZSE:000028) Low P/E No Reason For Excitement
Aug 13Estimating The Intrinsic Value Of China National Accord Medicines Corporation Ltd. (SZSE:000028)
Jul 12Is China National Accord Medicines (SZSE:000028) A Risky Investment?
Jun 12Improved Earnings Required Before China National Accord Medicines Corporation Ltd. (SZSE:000028) Shares Find Their Feet
May 12Analysts Are Updating Their China National Accord Medicines Corporation Ltd. (SZSE:000028) Estimates After Its Full-Year Results
Apr 10China National Accord Medicines Corporation Ltd. (SZSE:000028) Shares Could Be 28% Below Their Intrinsic Value Estimate
Mar 15China National Accord Medicines (SZSE:000028) Has A Rock Solid Balance Sheet
Feb 29Opbrengsten en kosten
Hoe China National Accord Medicines geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Sep 24 | 75,358 | 1,475 | 6,501 | 28 |
| 30 Jun 24 | 74,876 | 1,512 | 6,474 | 28 |
| 31 Mar 24 | 75,881 | 1,626 | 6,461 | 31 |
| 31 Dec 23 | 75,477 | 1,599 | 6,480 | 27 |
| 30 Sep 23 | 75,412 | 1,629 | 6,550 | 27 |
| 30 Jun 23 | 75,702 | 1,643 | 6,554 | 21 |
| 31 Mar 23 | 74,979 | 1,597 | 6,476 | 11 |
| 31 Dec 22 | 73,443 | 1,487 | 6,396 | 9 |
| 30 Sep 22 | 72,765 | 1,310 | 6,121 | 0 |
| 30 Jun 22 | 71,324 | 1,269 | 6,024 | 0 |
| 31 Mar 22 | 69,459 | 1,260 | 5,974 | 0 |
| 31 Dec 21 | 68,358 | 1,336 | 5,816 | 0 |
| 30 Sep 21 | 66,979 | 1,478 | 5,758 | 0 |
| 30 Jun 21 | 65,643 | 1,500 | 5,582 | 0 |
| 31 Mar 21 | 62,875 | 1,482 | 5,205 | 0 |
| 31 Dec 20 | 59,649 | 1,402 | 4,946 | 0 |
| 30 Sep 20 | 56,244 | 1,306 | 4,536 | 0 |
| 30 Jun 20 | 54,358 | 1,262 | 4,268 | 0 |
| 31 Mar 20 | 53,539 | 1,217 | 4,164 | 0 |
| 31 Dec 19 | 52,787 | 1,268 | 4,020 | 0 |
| 30 Sep 19 | 50,779 | 1,243 | 3,981 | 0 |
| 30 Jun 19 | 47,943 | 1,218 | 3,837 | 0 |
| 31 Mar 19 | 44,937 | 1,217 | 3,681 | 0 |
| 31 Dec 18 | 43,122 | 1,211 | 3,525 | 0 |
| 30 Sep 18 | 41,751 | 1,182 | 3,316 | 0 |
| 30 Jun 18 | 41,517 | 1,143 | 3,205 | 0 |
| 31 Mar 18 | 41,298 | 1,078 | 3,087 | 0 |
| 31 Dec 17 | 41,263 | 1,058 | 3,030 | 0 |
| 30 Sep 17 | 41,418 | 1,080 | 2,973 | 0 |
| 30 Jun 17 | 41,211 | 1,084 | 2,993 | 0 |
| 31 Mar 17 | 41,159 | 1,205 | 2,979 | 0 |
| 31 Dec 16 | 41,248 | 1,187 | 3,027 | 0 |
| 30 Sep 16 | 49,249 | 1,263 | 4,452 | 0 |
| 30 Jun 16 | 45,568 | 1,199 | 3,926 | 0 |
| 31 Mar 16 | 41,870 | 984 | 3,415 | 0 |
| 31 Dec 15 | 37,819 | 928 | 2,899 | 0 |
| 30 Sep 15 | 25,740 | 721 | 974 | 0 |
| 30 Jun 15 | 25,155 | 693 | 941 | 0 |
| 31 Mar 15 | 24,683 | 682 | 990 | 0 |
| 31 Dec 14 | 23,954 | 652 | 976 | 0 |
| 30 Sep 14 | 23,418 | 629 | 944 | 0 |
| 30 Jun 14 | 22,680 | 607 | 949 | 0 |
| 31 Mar 14 | 21,864 | 545 | 911 | 0 |
| 31 Dec 13 | 21,199 | 520 | 886 | 0 |
Kwaliteitswinsten: 000028 has high quality earnings.
Groeiende winstmarge: 000028's current net profit margins (2%) are lower than last year (2.2%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 000028's earnings have grown by 4.9% per year over the past 5 years.
Versnelling van de groei: 000028's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Winst versus industrie: 000028 had negative earnings growth (-9.4%) over the past year, making it difficult to compare to the Healthcare industry average (-5.7%).
Rendement op eigen vermogen
Hoge ROE: 000028's Return on Equity (7.4%) is considered low.